Harnessing deep learning
to prevent blindness
Learn how Eyenuk can help
Eyenuk Appoints Mads Dall as Chairman of the Board and Gaurav Agarwal as Chief Executive Officer
Los Angeles, Jan. 06, 2025 — Eyenuk, a global artificial intelligence (AI) digital health company and leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, today announced the appointment of Mads Dall as…
Eyenuk Supports Federal Efforts to Promote Nationwide Adoption of Interoperable Standards for Ophthalmic Imaging Data
LOS ANGELES, November 28th, 2023 – Eyenuk, Inc., a leading global digital health company specializing in artificial intelligence (AI), today stands shoulder to shoulder with the National Eye Institute (NEI), U.S. Food and Drug Administration…
New FDA Clearance Makes Eyenuk the First Company with Multiple Cameras for Autonomous AI Detection of Diabetic Retinopathy
This clearance expands the label of its flagship product, the EyeArt® AI system, broadening the choice for primary care clinics to screen people with diabetes Company’s FDA clearance also includes Real-Time Image Quality Feedback and…
Eyenuk Welcomes Paul Praino as Chief Commercial Officer
Leads Expansion of Commercial Team Toward Next Stage of Growth LOS ANGELES – February 16, 2023 – Eyenuk, a global artificial intelligence (AI) digital health company, and the leader in real-world applications for AI Eye…
Eyenuk Secures the First European Union MDR Certification for Autonomous AI Detection of Diabetic Retinopathy, Age-Related Macular Degeneration, and Glaucoma
The approval allows Eyenuk’s AI eye screening system, already approved for detection of diabetic retinopathy, to aid millions of additional patients at risk for vision loss LOS ANGELES, January 31, 2023 – Eyenuk, a global…
Introducing EyeArt®
EyeArt is the first FDA cleared AI technology for autonomous detection of both more than mild and vision-threatening diabetic retinopathy. The EyeArt® AI Eye Screening System is the most extensively validated autonomous AI technology, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.
* EyeArt® has US FDA clearance, CE marking as a class IIb medical device in the European Union, and a Health Canada license.
How can EyeArt Help?
The EyeArt system provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation, enabling imaging, grading and reporting in a single office visit.
What does EyeArt Do?
The EyeArt system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects signs of disease, and returns an easy-to-read report in under 60 seconds.
How does EyeArt Work?
The EyeArt system incorporates a number of deep learning and image analysis algorithms to automatically assess the quality of the images, detect the presence and extent of lesions, and determine level of disease based on internationally recognized clinical scales.
Why choose EyeArt?
The EyeArt system is the world’s most-validated artificial intelligence (AI) screening tool for diabetic retinopathy, demonstrating high real-world sensitivity and specificity. It is proven to be safe, fast, and consistent.
Exceptional Performance in Pivotal, Prospective, Multi-Center Clinical Trial
Dr. Jennifer I. Lim, MD, Marion H. Schenk Esq. Chair, Professor of Ophthalmology, and Director of Retina Service at the University of Illinois at Chicago presented the Eyenuk Clinical Trial study results at the ARVO 2019 Imaging in the Eye Conference in Vancouver, Canada. Dr. Lim spoke to MD Magazine about the study in a multi part interview series. Click on the video to watch the interview.
Our Product Suite
Products under development. Click here to know more.
*EyeMark™, EyeReadUWF™ have not yet been cleared for sales in any region.
Eyenuk in the news
Select Collaborators, Customers, & Partners
The Doheny Eye Institute in Los Angeles, CA is recognized as a leading center for eye disease and vision research.
The Los Angeles County Department of Health Services safety net serves more than 800K patients annually and runs a teleretinal DR screening program.
Madras Diabetes Research Foundation (MDRF) in India was established in 1996. It's a premier research institute for diabetes and its complications.
Washington University School of Medicine, St. Louis, MO is one of the leading medical research, teaching and patient care institutions in the US.
The Armenian Eyecare Project (AECP) is a nonprofit organization dedicated to providing the Armenian people eye care to help eliminate preventable blindness.
Diabetes Clinic Bad Mergentheim (Germany) is a specialist hospital for inpatient diabetes treatment.
The National Health Service (NHS) is the public health service system of the United Kingdom. NHS runs the largest DR screening program in the world.
CAMO, the Ambrosian Ophthalmic Center, is an eye clinic of excellence, in Milan, for diagnostics, correction of visual defects and treatment of eye diseases.
Eye Picture Archive Communication System is a non-proprietary web-based application for exchanging eye-related clinical information.